Colistin dosing and nephrotoxicity in a large community teaching hospital

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4503-4505

  DeRyke, C Andrew ^a   Crawford, Amanda J ^b,d   Uddin, Nizam ^c   Wallace, Mark R ^a  

^a ORLANDO HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; CREATININE; DIURETIC AGENT; HYPERTENSIVE AGENT;

ADULT; AGE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COMMUNITY HOSPITAL; CREATININE BLOOD LEVEL; DRUG OVERDOSE; FEMALE; HUMAN; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; NEPHROTOXICITY; OBESITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; TEACHING HOSPITAL; TREATMENT DURATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BODY WEIGHT; COLISTIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALS, COMMUNITY; HOSPITALS, TEACHING; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 77957346292     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01707-09     Document Type: Article

References (19)

1. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
2. Devine, B. 1974. Gentamicin therapy. Drug Intell. Clin. Pharm. 8:650-655.
3. Evans, M. E., D. J. Feola, and R. P. Rapp. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 33:960-967.
4. Falagas, M. E., K. N. Fragoulis, S. K. Kasiakou, G. J. Sermaidis, and A. Michalopoulos. 2005. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents 26:504-507.
5. Falagas, M. E., S. K. Kasiakou, D. P. Kofteridis, G. Roditakis, and G. Samonis. 2006. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 25:596-599.
6. Falagas, M. E., P. I. Rafailidis, S. K. Kasiakou, P. Hatzopoulou, and A. Michalopoulos. 2006. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin. Microbiol. Infect. 12:1227-1230.
7. Falagas, M. E., M. Rizos, I. A. Bliziotis, K. Rellos, S. K. Kasiakou, and A. Michalopoulos. 2005. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect. Dis. 5:1.
8. Hartzell, J. D., R. Neff, J. Ake, R. Howard, S. Olson, K. Paolino, M. Vishnepolsky, A. Weintrob, and G. Wortmann. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48:1724-1728.
9. Kellum, J. A., R. Bellomo, and C. Ronco. 2008. Definition and classification of acute kidney injury. Nephron Clin. Pract. 109:c182-c187.
10. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
11. Levin, A. S., A. A. Barone, J. Penco, M. V. Santos, I. S. Marinho, E. A. Arruda, E. I. Manrique, and S. F. Costa. 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28:1008-1011.
12. Li, J., K. Coulthard, R. Milne, R. L. Nation, S. Conway, D. Peckham, C. Etherington, and J. Turnidge. 2003. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52:987-992.
13. Li, J., R. L. Nation, J. D. Turnidge, R. W. Milne, K. Coulthard, C. R. Rayner, and D. L. Paterson. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
14. Li, J., C. R. Rayner, R. L. Nation, R. Deans, R. Boots, N. Widdecombe, A. Douglas, and J. Lipman. 2005. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob. Agents Chemother. 49:4814-4815.
15. Markou, N., H. Apostolakos, C. Koumoudiou, M. Athanasiou, A. Koutsoukou, I. Alamanos, and L. Gregorakos. 2003. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care 7:R78-R83.
16. Markou, N., S. L. Markantonis, E. Dimitrakis, D. Panidis, E. Boutzouka, S. Karatzas, P. Rafailidis, H. Apostolakos, and G. Baltopoulos. 2008. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin. Ther. 30:143-151.
17. Nation, R. L., and J. Li. 2009. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22:535-543.
18. Plachouras, D., M. Karvanen, L. E. Friberg, E. Papadomichelakis, A. Antoniadou, I. Tsangaris, I. Karaiskos, G. Poulakou, F. Kontopidou, A. Armaganidis, O. Cars, and H. Giamarellou. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother. 53:3430-3436.
19. Wallace, S. J., J. Li, R. L. Nation, C. R. Rayner, D. Taylor, D. Middleton, R. W. Milne, K. Coulthard, and J. D. Turnidge. 2008. Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob. Agents Chemother. 52:1159-1161.